<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122667">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505699</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000720304</org_study_id>
    <secondary_id>ECOG-E2993T4</secondary_id>
    <nct_id>NCT01505699</nct_id>
  </id_info>
  <brief_title>Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help
      doctors identify and learn more about biomarkers related to cancer.

      PURPOSE: This research study is studying biomarkers in samples from patients with acute
      lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To identify microRNAs that behave as oncogenes or as tumor suppressor genes in
           B-lineage acute lymphoblastic leukemia (ALL) in vitro and in vivo.

        -  To examine if single microRNA or signatures of microRNA correspond to different
           clinical outcomes in cytogenetically distinct B-ALL groups.

      OUTLINE: RNA from archived samples are analyzed for microRNA expression profile in vitro and
      in vivo.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Comprehensive view of microRNA expression by cytogenetic subgroup</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>MicroRNA expression in relation to clinical outcome</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Differential microRNA expression between normal B-cells and progenitors compared to B-ALL</measure>
  </primary_outcome>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Samples from patients enrolled on ECOG-2993

          -  Samples from patients with recurrent cytogenetic abnormalities other than BCR-ABL,
             including MLL/AF4, E2A/PBX1, and TEL/AML1

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Guido Wendel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>January 4, 2012</lastchanged_date>
  <firstreceived_date>January 4, 2012</firstreceived_date>
  <responsible_party>
    <name_title>Robert L. Comis</name_title>
    <organization>ECOG Group Chair's Office</organization>
  </responsible_party>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>B-cell adult acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
